Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$41.44
-0.5%		$46.44
$27.00
▼
$55.67
$6.95B0.322.15 million shs1.82 million shs
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$15.50
$15.51
$9.20
▼
$15.73
$1.82B0.972.20 million shsN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
$32.04
-0.2%		$38.89
$16.04
▼
$45.42
$6.62B0.841.51 million shs1.13 million shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$80.85
+0.9%		$95.17
$16.04
▼
$110.18
$7.11B3.11.13 million shs2.72 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
-2.60%+2.08%-9.65%-23.28%+34.40%
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.00%0.00%0.00%0.00%+52.86%
Immunovant, Inc. stock logo
IMVT
Immunovant
-3.43%-4.03%-18.19%-20.34%+94.02%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-13.60%-5.44%-9.97%-16.03%+380.56%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$41.44
-0.5%		$46.44
$27.00
▼
$55.67
$6.95B0.322.15 million shs1.82 million shs
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$15.50
$15.51
$9.20
▼
$15.73
$1.82B0.972.20 million shsN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
$32.04
-0.2%		$38.89
$16.04
▼
$45.42
$6.62B0.841.51 million shs1.13 million shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$80.85
+0.9%		$95.17
$16.04
▼
$110.18
$7.11B3.11.13 million shs2.72 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
-2.60%+2.08%-9.65%-23.28%+34.40%
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.00%0.00%0.00%0.00%+52.86%
Immunovant, Inc. stock logo
IMVT
Immunovant
-3.43%-4.03%-18.19%-20.34%+94.02%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-13.60%-5.44%-9.97%-16.03%+380.56%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.74
Moderate Buy$54.4731.44% Upside
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
1.50
ReduceN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
2.58
Moderate Buy$44.0037.33% Upside
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
2.88
Moderate Buy$109.7135.70% Upside

Current Analyst Ratings Breakdown

Latest DVAX, SYRE, ALKS, and IMVT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/1/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$121.00
10/1/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$110.00
9/24/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/24/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingPositive
9/24/2026
Alkermes plc stock logo
ALKS
Alkermes
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$50.00
9/24/2026
Alkermes plc stock logo
ALKS
Alkermes
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold$50.00
9/23/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/22/2026
Alkermes plc stock logo
ALKS
Alkermes
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$56.00
9/22/2026
Alkermes plc stock logo
ALKS
Alkermes
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$58.00 ➝ $61.00
9/21/2026
Alkermes plc stock logo
ALKS
Alkermes
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.67B4.17$1.62 per share25.54$11.02 per share3.76
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$330.51M5.51$0.16 per share97.88$4.54 per share3.41
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.19 per shareN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$890K7,988.71N/AN/A$7.21 per share11.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$241.66M$0.38109.06172.67N/A3.96%4.15%2.19%10/28/2026 (Estimated)
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$27.31M-$0.37N/A31.63N/A-13.13%7.18%4.08%N/A
Immunovant, Inc. stock logo
IMVT
Immunovant
-$505.61M-$2.82N/AN/AN/AN/A-69.59%-62.49%11/9/2026 (Estimated)
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$155.20M-$1.95N/AN/AN/AN/A-30.74%-22.23%11/3/2026 (Estimated)

Latest DVAX, SYRE, ALKS, and IMVT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.7778N/AN/AN/AN/AN/A
10/28/2026Q3 2026
Alkermes plc stock logo
ALKS
Alkermes
-$0.0781N/AN/AN/A$463.47 millionN/A
8/6/2026Q1 2027
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.6289-$0.75-$0.1211-$0.75$7.10 million$7.10 million
8/4/2026Q2 2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.7589-$0.36+$0.3989-$0.36N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
0.82
2.30
1.85
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.41
7.62
6.94
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
7.27
7.27
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
18.53
18.53

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
96.96%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.59%
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
2.98%
Immunovant, Inc. stock logo
IMVT
Immunovant
1.90%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
15.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,050167.76 million160.06 millionOptionable
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
350117.43 million113.93 millionOptionable
Immunovant, Inc. stock logo
IMVT
Immunovant
315206.55 million202.63 millionOptionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
11287.94 million74.14 millionOptionable

Recent News About These Companies

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock - October 5, 2026
October 6 at 6:50 PM  |  biospace.comB
Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market
October 6 at 6:50 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spyre-therapeutics-sinks-14-upsized-174005484.html
Spyre Therapeutics Prices $350 Million Common Stock Offering; Shares Down Pre-Bell
October 6 at 6:50 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spyre-therapeutics-prices-350-million-085923640.html
Spyre Therapeutics (NASDAQ:SYRE) Stock Falls 12.7% - Should You Sell?
October 6 at 11:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-spyre-therapeutics-nasdaq-syre-stock-falls-127-should-you-sell-2026-10-06/
Spyre Therapeutics Prices $350 Mln Public Offering Of Shares
October 6 at 7:50 AM  |  rttnews.comhttps://www.rttnews.com/3696653/spyre-therapeutics-prices-350-mln-public-offering-of-shares.aspx
Spyre Therapeutics prices $350M public offering at $85 per share
October 6 at 7:50 AM  |  msn.comhttps://www.msn.com/en-us/science/biochemistry/spyre-therapeutics-prices-350m-public-offering-at-85-per-share/ar-AA2dEsOS
Spyre Therapeutics Commences Public Offering of Common Stock
October 5 at 8:18 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spyre-therapeutics-commences-public-offering-201711030.html
Spyre Therapeutics stock falls on public offering launch
October 5 at 8:18 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/spyre-therapeutics-stock-falls-public-204622016.html
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
October 5 at 8:13 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375081/0/en/spyre-therapeutics-announces-pricing-of-350-0-million-public-offering-of-common-stock.html
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
October 5 at 4:01 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/05/3374974/0/en/spyre-therapeutics-announces-proposed-public-offering-of-its-common-stock.html
Spyre Therapeutics Announces Grants of Inducement Awards - October 2, 2026
October 5 at 10:17 AM  |  biospace.comB
Wells Fargo Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)
October 4 at 11:15 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4951908/wells-fargo-reaffirms-their-buy-rating-on-spyre-therapeutics-syre/
Spyre (NASDAQ: SYRE) legal chief trims stake in planned share sale
October 4 at 12:00 PM  |  defenseworld.netD
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows Sells 7,500 Shares of Stock
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083219
Spyre Therapeutics (NASDAQ:SYRE) Stock: Insider Scott Burrows Sells 7,500 Shares
October 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-syre-insider-buying-and-selling-2026-10-03/
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows Sells 17,500 Shares of Stock
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082819
Spyre Therapeutics (NASDAQ:SYRE) Insider Heidy King-Jones Sells 28,933 Shares of Stock
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082818
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares of Stock
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082796
Spyre Therapeutics (NASDAQ:SYRE) Earns "Buy" Rating from BTIG Research
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081794
JPMorgan Chase & Co. Begins Coverage on Spyre Therapeutics (NASDAQ:SYRE)
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081549
Spyre Therapeutics (NASDAQ:SYRE) Upgraded at Wall Street Zen
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081178

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Curaleaf logo illuminated on a lobby wall, with cannabis plants visible through windows in the background.
Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
By Jeffrey Neal Johnson | September 15, 2026
Intel logo displayed on a computer chip embedded in an illuminated blue circuit board.
Intel's Ohio Lifeline? Why the SK Hynix Talks Matter
By Chris Markoch | September 18, 2026
Alkermes stock logo

Alkermes NASDAQ:ALKS

$41.44 -0.21 (-0.50%)
Closing price 04:00 PM Eastern
Extended Trading
$41.09 -0.35 (-0.84%)
As of 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Dynavax Technologies stock logo

Dynavax Technologies NASDAQ:DVAX

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$32.04 -0.07 (-0.22%)
Closing price 04:00 PM Eastern
Extended Trading
$32.04 0.00 (0.00%)
As of 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$80.85 +0.74 (+0.92%)
Closing price 04:00 PM Eastern
Extended Trading
$81.91 +1.06 (+1.31%)
As of 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas